GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

The UPLC system was configured with an Acquity Premier Oligonucleotide C18 column (1.7 µm, 2.1 × 50 mm). The aqueous and ...

Madrigal is eying an expansion of Rezdiffra’s capabilities via combination with precision siRNA gene silencing.

Researchers found a modified peptide carrier that was delivering the siRNA drug by adhering to and potentially moving along cell filopodia, leading to more efficient cell entry and improved gene ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...

siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...